T. Rowe Price Associates
TRDA icon

T. Rowe Price Associates’s Entrada Therapeutics TRDA Stock Holding History

T. Rowe Price Associates’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.99M Buy
542,316
+16,273
+3% +$156K ﹤0.01% 1677
2026
Q1 		$6.64M Buy
526,043
+198,620
+61% +$2.28M ﹤0.01% 1321
2025
Q4 		$3.37M Sell
327,423
-33,103
-9% -$279K ﹤0.01% 1531
2025
Q3 		$2.09M Sell
360,526
-2,206,952
-86% -$12.9M ﹤0.01% 1710
2025
Q2 		$17.3M Sell
2,567,478
-169,289
-6% -$1.36M ﹤0.01% 988
2025
Q1 		$24.7M Sell
2,736,767
-166,258
-6% -$2.07M ﹤0.01% 900
2024
Q4 		$50.2M Sell
2,903,025
-146,547
-5% -$2.66M 0.01% 752
2024
Q3 		$48.7M Sell
3,049,572
-84,886
-3% -$1.34M 0.01% 765
2024
Q2 		$44.7M Buy
3,134,458
+381,101
+14% +$5.42M 0.01% 757
2024
Q1 		$39M Sell
2,753,357
-256,316
-9% -$3.62M ﹤0.01% 787
2023
Q4 		$45.4M Buy
3,009,673
+9,636
+0.3% +$143K 0.01% 737
2023
Q3 		$47.4M Buy
3,000,037
+61,729
+2% +$972K 0.01% 698
2023
Q2 		$44.5M Sell
2,938,308
-45,555
-2% -$628K 0.01% 736
2023
Q1 		$43.3M Sell
2,983,863
-30,514
-1% -$407K 0.01% 716
2022
Q4 		$40.8M Buy
3,014,377
+42,327
+1% +$742K 0.01% 717
2022
Q3 		$46.8M Buy
2,972,050
+534,552
+22% +$6.79M 0.01% 668
2022
Q2 		$29.7M Sell
2,437,498
-57,216
-2% -$434K ﹤0.01% 1052
2022
Q1 		$23.4M Buy
2,494,714
+474,077
+23% +$5.08M ﹤0.01% 1193
2021
Q4 		$34.6M Buy
+2,020,637
New +$49M ﹤0.01% 1127

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

T. Rowe Price Associates's TRDA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Entrada Therapeutics (TRDA) stake by 3.1% in Q2 2026, buying an estimated $156K and bringing the position to 542,316 shares worth $3.99M. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

T. Rowe Price Associates first reported a position in TRDA in Q4 2021 and has held it in 19 quarters since. The position peaked at $50.2M in Q4 2024. 129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • T. Rowe Price Associates held 542,316 shares of Entrada Therapeutics worth $3.99M as of Q2 2026.
  • T. Rowe Price Associates bought 16,273 Entrada Therapeutics shares in Q2 2026, an estimated $156K.
  • Entrada Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1677 holding.
  • T. Rowe Price Associates first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • T. Rowe Price Associates's Entrada Therapeutics position peaked at $50.2M in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.